Literature DB >> 36225631

Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Madhuri Jayathirtha1, Anca-Narcisa Neagu2, Danielle Whitham1, Shelby Alwine1, Costel C Darie1.   

Abstract

MCF7 is a commonly used luminal type A non-invasive/poor-invasive human breast cancer cell line that does not usually migrate or invade compared with MDA-MB-231 highly metastatic cells, which emphasize an invasive and migratory behavior. Under special conditions, MCF7 cells might acquire invasive features. The aberration in expression and biological functions of the jumping translocation breackpoint (JTB) protein is associated with malignant transformation of cells, based on mitochondrial dysfunction, inhibition of tumor suppressive function of TGF-β, and involvement in cancer cell cycle. To investigate new putative functions of JTB by cellular proteomics, we analyzed the biological processes and pathways that are associated with the JTB protein downregulation. The results demonstrated that MCF7 cell line developed a more "aggressive" phenotype and behavior. Most of the proteins that were overexpressed in this experiment promoted the actin cytoskeleton reorganization that is involved in growth and metastatic dissemination of cancer cells. Some of these proteins are involved in the epithelial-mesenchymal transition (EMT) process (ACTBL2, TUBA4A, MYH14, CSPG5, PKM, UGDH, HSP90AA2, and MIF), in correlation with the energy metabolism reprogramming (PKM, UGDH), stress-response (HSP10, HSP70A1A, HSP90AA2), and immune and inflammatory response (MIF and ERp57-TAPBP). Almost all upregulated proteins in JTB downregulated condition promote viability, motility, proliferation, invasion, survival into a hostile microenvironment, metabolic reprogramming, and escaping of tumor cells from host immune control, leading to a more invasive phenotype for MCF7 cell line. Due to their downregulated condition, four proteins, such as CREBZF, KMT2B, SELENOS and CACNA1I are also involved in maintenance of the invasive phenotype of cancer cells, promoting cell proliferation, migration, invasion and tumorigenesis. Other downregulated proteins, such as MAZ, PLEKHG2, ENO1, TPI2, TOR2A, and CNNM1, may promote suppression of cancer cell growth, invasion, EMT, tumorigenic abilities, interacting with glucose and lipid metabolism, disrupting nuclear envelope stability, or suppressing apoptosis and developing anti-angiogenetic activities. Therefore, the main biological processes and pathways that may increase the tumorigenic potential of the MCF7 cells in JTB downregulated condition are related to the actin cytoskeleton organization, EMT, mitotic cell cycle, glycolysis and fatty acid metabolism, inflammatory response and macrophage activation, chemotaxis and migration, cellular response to stress condition (oxidative stress and hypoxia), transcription control, histone modification and ion transport. AJCR
Copyright © 2022.

Entities:  

Keywords:  Breast cancer; JTB downregulated condition; jumping translocation breakpoint (JTB) protein; proteomics

Year:  2022        PMID: 36225631      PMCID: PMC9548009     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  187 in total

Review 1.  Selenoproteins in colon cancer.

Authors:  Kristin M Peters; Bradley A Carlson; Vadim N Gladyshev; Petra A Tsuji
Journal:  Free Radic Biol Med       Date:  2018-05-22       Impact factor: 7.376

2.  [Downregulation of PAR expression induces the apoptosis of human prostate cancer PC3 cells and increases the Bcl-2/Bax ratio].

Authors:  Xiao-Feng Xu; Xiu-Min Zhou; Zhi-Feng Wei; Zheng-Yu Zhang; Jing-Ping Ge; Wu Wei; Wen-Quan Zhou; Wen Cheng; Jian-Quan Hou; Jian-Ping Gao
Journal:  Zhonghua Nan Ke Xue       Date:  2012-10

3.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

4.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

5.  Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.

Authors:  K Kim; G Chadalapaka; S-O Lee; D Yamada; X Sastre-Garau; P-A Defossez; Y-Y Park; J-S Lee; S Safe
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

6.  Classification of Genes Based on Age-Related Differential Expression in Breast Cancer.

Authors:  Gunhee Lee; Minho Lee
Journal:  Genomics Inform       Date:  2017-12-29

7.  Differential role of nonmuscle myosin II isoforms during blebbing of MCF-7 cells.

Authors:  Sumit K Dey; Raman K Singh; Shyamtanu Chattoraj; Shekhar Saha; Alakesh Das; Kankan Bhattacharyya; Kaushik Sengupta; Shamik Sen; Siddhartha S Jana
Journal:  Mol Biol Cell       Date:  2017-03-01       Impact factor: 4.138

8.  Up-regulation of long noncoding RNA MBNL1-AS1 suppresses breast cancer progression by modulating miR-423-5p/CREBZF axis.

Authors:  Jun Fang; Gaohui Jiang; Weiguo Mao; Lili Huang; Chen Huang; Shanshan Wang; Huimin Xue; Jing Ke; Qichao Ni
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

9.  A pan-cancer transcriptomic study showing tumor specific alterations in central metabolism.

Authors:  Ilir Sheraj; N Tulin Guray; Sreeparna Banerjee
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

10.  In vitro gentamicin exposure alters caveolae protein profile in cochlear spiral ligament pericytes.

Authors:  Elisa Ghelfi; Yohann Grondin; Emil J Millet; Adam Bartos; Magda Bortoni; Clara Oliveira Gomes Dos Santos; Humberto J Trevino-Villarreal; Rosalinda Sepulveda; Rick Rogers
Journal:  Proteome Sci       Date:  2018-03-16       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.